This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07626515 |
|---|---|
| Status | Active not recruiting |
| Phase | Phase 1 |
| Sponsor | Hoffmann-La Roche |
| Enrollment | 36 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Healthy Participants |
| Interventions | Enicepatide; Placebo |
| Start | Jul 2, 2026 |
| Primary completion | Apr 8, 2027 |
| Study completion | Apr 8, 2027 |
| Results posted | Not yet |
| Registry last updated | Nov 5, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
This is a Phase I, randomized, double-blinded, placebo-controlled, study to assess the safety, tolerability, and pharmacokinetics (PK) of enicepatide in generally healthy adult Chinese participants with body mass index (BMI) ≥23.0 kilograms per meter squared (kg/m^2).
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Incidence and Severity of Adverse Events | Baseline to Safety Follow-Up (27 weeks) |
| Number of Participants with Abnormal Clinical Laboratory Parameters as a Shift from Baseline to Maximum Postbaseline Severity Grade | Baseline to Safety Follow-Up (27 weeks) |
| Change from Baseline in Pulse Rate | At prespecified time points from Baseline to Safety Follow-Up (27 weeks) |
| Change from Baseline in Respiratory Rate | At prespecified time points from Baseline to Safety Follow-Up (27 weeks) |
| Change from Baseline in Systolic Blood Pressure | At prespecified time points from Baseline to Safety Follow-Up (27 weeks) |
| Change from Baseline in Diastolic Blood Pressure | At prespecified time points from Baseline to Safety Follow-Up (27 weeks) |
| Change from Baseline in Body Temperature | At prespecified time points from Baseline to Safety Follow-Up (27 weeks) |
7 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 17, 2026. See the trial changes feed for what has changed recently.
More trials of Enicepatide (CT-388)
- Enicepatide: Phase 3 Trial (NCT07670416)
- Enicepatide: Phase 3 Trial (NCT07351058)
- Enicepatide: Phase 3 Trial in Obesity (NCT07351045)
- Enicepatide: Phase 2 Trial (NCT06628362)
- Enicepatide: Phase 2 Trial in Obesity (NCT06525935)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.